| | Year | Author | Patients | Response to chemoradiotherapy | P value | Long-term survival | | 5-year OS (%) | value | 5-year DFS (%) | value |
| | 2006 | Sengul et al. [8] | Mucinous, 16
| TRG1, 1 (6%); TRG2, 2 (12.5%); TRG3, 3 (19%);
TRG4, 6 (37.5%); TRG5, 4 (25%) | 0.002 (TRG) | NA | NA | NA | NA | | | T downstaging, 0; N downstaging, 18% | 0.009 (T downstaging) | NA | NA | | Nonmucinous, 46 | TRG1, 6 (13%); TRG2, 23 (50%); TRG3, 6 (13%);
TRG4, 11 (24%); TRG5, 0 | | T downstaging 25%, N downstaging 76% | 0.006 (N downstaging) |
| | 2007 | Grillo-Ruggieri et al. [9] | Mucinous, 25 | T downstaging 52%, N downstaging 64% | <0.05 | 89 | NS | 87.3 | NS | | Nonmucinous, 111 | T downstaging 74.4%, N downstaging 85.5% | 83.9 | 67.6 |
| | 2011 | Shin et al. [10] | Mucinous, 23 | T downstaging 54.9%, N downstaging 52.2% | 0.03 (T downstaging) | 64.8 | 0.049 | 58.7 | 0.045 | | Nonmucinous, 345 | T downstaging 30.4%, N downstaging 53.3% | NS (N downstaging) | 79.8 | 69.2 |
| | 2012 | Oberholzer et al. [11] | Mucinous, 21 | T downstaging 18.8%, N downstaging 27.2% | 0.012 (T downstaging) | NA | NA | NA | NA | | Nonmucinous, 67 | T downstaging 55.2%, N downstaging 80.7% | 0.007 (N downstaging) | NA | NA |
| | 2014 | Yu et al. [12] | Mucinous, 60 | T downstaging 23% | 0.01 | 69 | 0.04 | 48 | 0.006 | | Nonmucinous, 270 | T downstaging 40% | 79 | 71 |
| | 2015 | Hugen et al. [13] | Mucinous, 58 | T downstaging 55.2% | 0.039 | 64.3 | 0.459 | NA | NA | | Nonmucinous, 482 | T downstaging 68.7% | 70.6 | NA |
|
|
